EPL-Indovida merger gets CCI nod for $2bn deal

What the CCI approval means for EPL

India’s competition regulator, the Competition Commission of India (CCI), has approved the proposed merger of Indovida India Private Limited with and into EPL Limited (NSE: EPL). The approval was disclosed on May 26, 2026, through a CCI release and a separate post by the regulator on X.

The combination is structured as a merger by absorption, where Indovida India will merge into EPL and EPL will continue as the listed entity. For EPL, the clearance is an important regulatory step because the merger is a statutory process that still requires additional approvals.

The deal was originally announced in March 2026, when EPL and Indovida India said they planned to create a larger consumer packaging entity with a combined valuation of about USD 2 billion. The CCI approval now moves the process forward to the next stages.

Deal structure: merger by absorption and share swap

Under the scheme, EPL will absorb Indovida India, a structure that typically results in the transfer of Indovida’s business and assets into EPL. In return, EPL will issue and allot new shares to Indovida India’s shareholders on a proportionate basis, according to the CCI release.

This mechanism effectively converts an indirect holding into a direct listed equity stake in EPL for Indovida’s shareholders. The article context also describes Indovida India as a subsidiary of a large petrochemical and packaging conglomerate, with the transaction bringing that interest directly onto EPL’s share register.

Separately disclosed deal terms from March 2026 describe the transaction as a share swap. The reported exchange ratio was 286 fully paid-up equity shares of EPL (face value ₹2 each) for every 10,000 fully paid-up equity shares of Indovida India (face value ₹10 each), based on recommendations from independent valuers.

Companies involved and what they do

EPL is a Mumbai-listed manufacturer of laminated tubes and packaging products. It serves multiple end markets including personal care, oral care, pharmaceutical, and food, as noted in the CCI-related context.

Indovida India is being merged into EPL through the absorption scheme. The merger is positioned as a step toward building a broader packaging platform, with a stronger multi-format product portfolio referenced in the March deal reporting.

Another detail highlighted in the March announcement is ownership context: EPL was described as being backed by Blackstone, alongside Indovida India as the counterparty in the combination.

Valuation and operating metrics disclosed in March

When the deal was announced in March 2026, the parties said the combined entity would have a valuation of about USD 2 billion. The March reporting also said EPL was valued at ₹339 per share as part of the merger framework, implying about a 70% premium over its last closing price at the time of the announcement.

Operationally, the combined packaging entity was reported to have revenues of ₹8,300 crore and EBITDA of around ₹1,750 crore. Another disclosed operating feature was its emerging markets orientation, with 75% of revenue expected from Asia, Africa, and Latin America.

The March coverage also stated that Indovida was valued at about a 35% discount relative to EPL’s multiple. In addition, potential synergies were cited in a range of USD 35 million to USD 50 million across cost and revenue streams.

Regulatory path: NCLT and other approvals still pending

While the CCI clearance is a major milestone, it is not the final approval needed to close the merger. The transaction is structured as a statutory merger and requires National Company Law Tribunal (NCLT) approval following the CCI nod.

The merger process was expected to take around 12 months, subject to regulatory and shareholder approvals, including majority of minority shareholder consent. A separate March filing context also mentioned that the scheme would require approvals from SEBI, stock exchanges, the CCI, the NCLT, and requisite shareholder majorities.

These steps are typical for large listed-company amalgamations in India and often determine the final timeline for completion.

Promoter and shareholding changes highlighted in deal coverage

The March deal reporting indicated that post-merger, Indorama Ventures would become the promoter with a 51.8% stake in the combined company. Another passage in the supplied context also stated that the promoter stake would increase from 25.97% to 68.37% after the merger.

Both figures were presented in the article inputs as part of merger coverage. The consistent theme across them is that the transaction reshapes the ownership profile of EPL and elevates Indorama’s role in the listed entity.

Market impact: what investors are likely to track next

From a market standpoint, the CCI approval reduces one key regulatory uncertainty, but investors typically focus on the remaining steps that determine closure and final terms. These include the NCLT process and shareholder voting thresholds, particularly the requirement for majority of minority shareholder consent mentioned in the deal context.

Investors will also track whether the share issuance to Indovida’s shareholders changes the free float, promoter holding, and governance structure. Another watch point is execution timelines because the process was described as taking around 12 months from the March announcement, assuming approvals progress as planned.

Key facts at a glance

Why the approval matters for the packaging sector

The deal is being positioned as the creation of a larger consumer packaging entity, combining capabilities across packaging formats and end markets. With EPL’s presence in laminated tubes and packaging products and Indovida’s integration into the listed company, the merged platform is framed as emerging markets-focused.

The disclosure of revenue and EBITDA scale, along with synergy estimates, indicates that the combination is expected to be driven by operating leverage and portfolio expansion. The ownership changes described in the deal reporting also suggest a strategic shift in control and long-term direction.

Conclusion

CCI’s approval on May 26, 2026 clears a key regulatory checkpoint for the proposed absorption merger of Indovida India into EPL. The transaction remains subject to further approvals, including the NCLT process and shareholder consents, before it can be completed.

The next updates investors are likely to watch for are procedural milestones in the NCLT-led scheme process and any subsequent filings or announcements on timelines and completion conditions.